Panitumumab-Induced Interstitial Lung Disease in a Case of Metastatic Colorectal Cancer

Publisher： Karger

E-ISSN： 2296-5262|36|4|209-212

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.36, Iss.4, 2013-03, pp. : 209-212

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Case of Panitumumab-Responsive Metastatic Rectal Cancer Initially Refractory to Cetuximab

By  

Case Reports in Oncology, Vol. 6, Iss. 2, 2013-07 ,pp. : 382-386

Karger

Access to resources Recommend Favorite

Erlotinib Achieved Partial Response in a Non-Small Cell Lung Cancer Patient with Gefitinib-Induced Interstitial Lung Disease

By  

Case Reports in Oncology, Vol. 4, Iss. 3, 2011-09 ,pp. : 464-466

Karger

Access to resources Recommend Favorite

Interstitial Lung Disease Induced by Drugs and Radiation

By  

Respiration, Vol. 71, Iss. 4, 2004-08 ,pp. : 301-326

Karger

Access to resources Recommend Favorite

Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC)

By Lawrence Donna   Maschio Michael   Leahy Kevin J.   Yunger Simon   Easaw Jacob C.   Weinstein Milton C.  

Journal of Medical Economics, Vol. 16, Iss. 12, 2013-12 ,pp. : 1387-1398

Informa Healthcare

Access to resources Recommend Favorite

Fatal Asymmetric Interstitial Lung Disease after Erlotinib for Lung Cancer

By  

Respiration, Vol. 84, Iss. 5, 2012-08 ,pp. : 431-435

Karger

Access to resources Recommend Favorite